Course Description
This learning segment allows the learner to practice what they have learned in microlearning segments 1 and 2 (tips and severity assessment). An AIMS examination is demonstrated allowing the learner to score the exam using the available AIMS scale. Next an instructor led review of the AIMS assessment scoring is provided allowing the learner to compare their assessment scores to the instructor.
Learning Objectives
- Demonstrate the important elements of an accurate AIMS assessment.
- Evaluate and score movements for a simulated AIMS assessment.
- Interpret the outcome of an AIMS assessment using a simulated interaction of a patient with tardive dyskinesia (TD).
Target Audience
If you are a pharmacist or other health care professional involved in the comprehensive medication management and/or care of patients at risk for tardive dyskinesia due to antipsychotic medications, we invite you to participate in this online course.
Faculty
View biographical information
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Complete the pre-test (if applicable) before starting the activity.
- Review the full content of the activity and reflect upon its teachings.
- Complete the post-test at the end of the activity no later than the closing activity date.
- Complete the evaluation at the end of the activity.
- If necessary, complete the post-test retest no later than the closing activity date.
- Receive a passing grade (70%).
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Dates: 06/08/2026-06/08/2029
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-26-038-H01-P
(Knowledge)
 | The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
View Faculty, Program Planning Committee/Reviewers Disclosures of Interest
Faculty:
- Steven Clark Stoner, PharmD, BCPP, FAAPP discloses: Speaker's Bureau and Advisory Board Tardive Dyskinesia: Neurocrine; Advisory Board Schizophrenia: Alkermes; Research PI Depression: Otsuka
Planning Committee:
- (Also peer reviewer) Leigh Anne Nelson, PharmD, BCPP, FAAPP discloses: Speaker's Bureau: Alkermes
- Steven Clark Stoner, PharmD, BCPP, FAAPP discloses: Speaker's Bureau and Advisory Board Tardive Dyskinesia: Neurocrine; Advisory Board Schizophrenia: Alkermes; Research PI Depression: Otsuka
*All identified conflicts of interest have been mitigated.
View AAPP's Disclaimer and Disclosure Declarations
AAPP Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Unlabeled Use Disclosure: Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. The faculty, planners, and American Association of Psychiatric Pharmacists do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
View AAPP's Copyright Statement, Terms of Use, and Policies
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View AAPP's Privacy Policy. AAPP's Terms of Use and other policies on education programs, resources, toolkits, and other web based content/offerings are available here.
View AAPP's Fair Balance and Integrity Statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.